Background Evidence for the management of chronic obstructive pulmonary disease
(COPD) comes from closely monitored efficacy trials involving groups of patients who were …

Background Whether the combination of a once-daily inhaled corticosteroid with a once-
daily longacting β 2 agonist is more protective than a once-daily longacting β 2 agonist …

BACKGROUND: Once-daily combination treatment is an attractive maintenance therapy for
COPD. However, the dose of inhaled corticosteroid to use in a once-daily combination is …

Fluticasone furoate/vilanterol trifenatate (FF/VI) is a once-daily inhaled corticosteroid/long-
acting β2-agonist combination in development for chronic obstructive pulmonary disease …

BACKGROUND: Fluticasone furoate (FF)/vilanterol (VI) is a novel once-daily inhaled
corticosteroid/long-acting β2-agonist combination therapy for COPD. We aimed to assess …

OBJECTIVES: COPD exacerbations are associated with significant morbidity and mortality.
This randomized, double-blind, parallel-group, multicenter study evaluated the effect of …

Rationale: Radiographically confirmed pneumonia risk with inhaled corticosteroid use in
chronic obstructive pulmonary disease (COPD) has not been assessed to date. Objectives …

Background: Guidelines recommend inhaled corticosteroids (ICS) as maintenance treatment
for patients with chronic obstructive pulmonary disease (COPD) with a post-bronchodilator …

Background Most guidelines recommend either a long-acting beta-agonist (LABA) plus an
inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice …

Chronic obstructive pulmonary disease (COPD) often coexists with other chronic diseases
and comorbidities that can markedly influence patients' health status and prognosis. This is …